Satsuma peels off fresh strip of long-term migraine study data ahead of planned FDA filing

Satsuma Pharmaceuticals is building the case for its nasally administered migraine therapy ahead of a planned filing for FDA approval early next year, reporting results from an ongoing open-label, long-term safety trial.